Oral Abstract Session 01 - Global HIV Vaccine Enterprise

PROGRAM / WEDNESDAY
20
Program
Wednesday, 12 September
07:30 – 12:30 Speaker Check-in BCEC Level 2, Room 251
08:00 – 14:00 Registration BCEC Level 3, Ballroom Foyer
08:30 – 10:30 Symposium 07: BCEC Level 3,
Priming Effective B Cell Responses Ballroom East
Chairs: Lynn Morris and Ralph Pantophlet
08:30 – 08:55 The Unique T Cell Receptor Expressed by Each Naive Helper T Cell S07.01
Instructs Effector Cell Fate
MK Jenkins
08:55 – 09:20 T Follicular Helper Cells in HIV Infection S07.02
H Streeck
09:20 – 09:45 Evolution of Broadly Cross-neutralizing Antibodies During HIV-1 Infection S07.03
PL Moore
09:45 – 10:10 Genetic and Structural Basis for Development of High Affinity Antibodies S07.04
J Crowe
10:10 – 10:25 CD40L Adjuvant for DNA/MVA Vaccine: Enhanced Protection from S07.05 OA
Acquisition of Neutralization Sensitive & Neutralization Resistant
Mucosal SIV Infections
S Kwa, S Sadagopal, J Hong, S Gangadhara, R Basu, L Lai, S Iyer,
K Araki, PL Earl, L Wyatt, F Villinger, B Moss, R Ahmed, RR Amara
08:30 – 10:30 Symposium 08: BCEC Level 2,
Therapeutic Vaccination and Strategies for the Cure Room 253 ABC
Chairs: Janet Siliciano and Xu Yu
08:30 – 08:55 Therapeutic Approaches to Curing HIV Infection S08.01
S Deeks
08:55 – 9:20 Therapeutic Vaccines in Strategies for Functional Cure of HIV S08.02
B Autran
09:20 – 09:45 Barriers to HIV-1 Eradication S08.03
R Siliciano
09:45 – 10:10 Persistence of Latently Infected CD4+ T Cells During HAART: S08.04
Keeping Memory, Keeping HIV
N Chomont
10:10 – 10:30 Assembling the Tools to Clear HIV Infection: Contributions from S08.05
Virology and Immunology
D Margolis
AIDS Vaccine 2012